Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
SOPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.58 - $4.92
Previous CloseN/A
Volume4.05K
Average Volume (3M)129.75K
Market Cap
$241.26M
Enterprise Value$193.51M
Total Cash (Recent Filing)$68.53M
Total Debt (Recent Filing)$30.13M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 05, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding66,831,070
10 Day Avg. Volume31,094
30 Day Avg. Volume129,749
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)2.78
Price to Sales (P/S)0.00
P/FCF Ratio-5.21
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit4.23
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$6.00Price Target Upside66.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
SOPHiA GENETICS News
PremiumCompany Announcements
SOPHiA GENETICS Announces Key Approvals at 2025 Annual General Meeting
PremiumCompany Announcements
SOPHiA GENETICS Releases 2024 ESG Impact Summary
PremiumCompany Announcements
SOPHiA GENETICS Q1 2025 Earnings Call Highlights
PremiumCompany Announcements
SOPHiA GENETICS to Hold Annual General Meeting Amidst Strategic Growth
PremiumCompany Announcements
SOPHiA GENETICS Reports Strong Q1 2025 Growth
PremiumCompany Announcements
SOPHiA GENETICS Reports Q1 2025 Financial Results
Bulls Say, Bears Say
Bulls Say
Customer GrowthThe company signed 28 new customers in the first quarter and implemented 33 new customers, which is a positive leading indicator for growth.
Market ExpansionManagement believes revenue re-acceleration will continue as key growth drivers take effect, including new customer additions and US market expansion.
Positive OutlookAnalyst maintains a positive view on SOPH shares due to the company's differentiated business model, large under-penetrated market, long-term upside drivers, and a solid balance sheet.
Bears Say
2024 HeadwindsThe company faced several headwinds in 2024 resulting in below long-term trend growth, notably from a lower biopharma revenue ramp and disruptions in LATAM.
Revenue DeclineSophia turned in a relatively challenging 2024 as they drove 4% revenue growth while growing their volumes by 11%, which implies a 6-7% decline in revenue per analysis, which declined in part due to headwinds with biopharma customers.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.14% Mutual Funds
3.84% Other Institutional Investors
94.94% Public Companies and
Individual Investors
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.58 and its highest was $4.92 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $241.26M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Aug 05, 2025 which is in 10 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on May 06, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.223 by -$0.037.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.21.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 66,831,070 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.223. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
SOPHiA GENETICS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (66.20% Upside)
$6.00 (66.20% Upside)
Blogger Sentiment
Bullish
SOPH Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.52%
12-Months-Change
Fundamentals
Return on Equity
-60.75%
Trailing 12-Months
Asset Growth
-18.61%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS (SOPH) is a health technology company that leverages data-driven medicine to enhance and expedite the analysis of genomic and radiomic data. The company operates within the biotechnology and healthcare sectors, providing a cloud-based software platform that enables healthcare institutions to analyze complex medical data to deliver insights that can improve patient outcomes. SOPHiA GENETICS' core product, the SOPHiA DDM™ platform, is designed to facilitate the interpretation of genomic data, thereby supporting various applications in oncology, rare diseases, and other health conditions.
SOPH Company Deck
SOPH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
SOPHiA GENETICS demonstrated strong revenue growth and customer expansion, particularly in the U.S. market, alongside successful cost management and strategic partnerships. However, challenges in Latin America and the biopharma segment presented some headwinds.Read More>SOPH Stock 12 Month Forecast
Average Price Target
$6.00
▲(66.20%Upside)